Apr 16, 2021
Immutep Receives A$1,155,055 R&D Tax Incentive
Apr 07, 2021
Immutep Achieves Fast Track Designation From US FDA For Efti, A Soluble Lag-3 Protein, In First Line Recurrent/Metastatic Head & Neck Cancer
Apr 06, 2021
Immutep Announces European Patent Grant For LAG525 Antibody In Combination Therapy
Mar 17, 2021
Immutep To Participate In A Fireside Chat At The Inaugural M Vest And Maxim Group Emerging Growth Virtual Conference
Mar 16, 2021
Immutep Enters Second Collaboration with MSD for a New Randomised Phase IIB Trial in Head and Neck Cancer
